Compare · AZN vs SEPN
AZN vs SEPN
Side-by-side comparison of AstraZeneca PLC (AZN) and Septerna Inc. (SEPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and SEPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $270.37B, about 147.3x SEPN ($1.84B).
- Over the past year, AZN is up 91.6% and SEPN is up 51.9% - AZN leads by 39.7 points.
- AZN has been more active in the news (23 items in the past 4 weeks vs 12 for SEPN).
- AZN has more recent analyst coverage (25 ratings vs 11 for SEPN).
- Company
- AstraZeneca PLC
- Septerna Inc.
- Price
- $174.42-0.54%
- $38.73-1.40%
- Market cap
- $270.37B
- $1.84B
- 1M return
- +1.07%
- -5.14%
- 1Y return
- +91.63%
- +51.94%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2024
- News (4w)
- 23
- 12
- Recent ratings
- 25
- 11
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Latest SEPN
- Chief Financial Officer Gil M Labrucherie sold $832,359 worth of shares (20,000 units at $41.62) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Finer Jeffrey exercised 18,500 shares at a strike of $2.76 and sold $807,015 worth of shares (18,500 units at $43.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.
- Director Ezekowitz Alan sold $3,934,363 worth of shares (81,820 units at $48.09) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 35,600 units (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.
- SEC Form 144 filed by Septerna Inc.
- SEC Form 10-Q filed by Septerna Inc.
- Septerna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
- Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits